Articles published in Advances in Pharmacoepidemiology and Drug Safety have been cited by esteemed scholars and scientists all around the world. Advances in Pharmacoepidemiology and Drug Safety has got h-index 14, which means every article in Advances in Pharmacoepidemiology and Drug Safety has got 14 average citations.

Following are the list of articles that have cited the articles published in Advances in Pharmacoepidemiology and Drug Safety.

  2022 2021 2020 2019 2018

Year wise published articles

30 32 23 3 4

Year wise citations received

71 95 59 87 69
Journal total citations count 654
Journal Impact Factor 2.86
Journal 5 years Impact Factor 4.33
Journal CiteScore 5.34
Journal h-index 14
Important citations

Keck T, Strobl A, Weinhaeusel A, Funk P, Michaelis M. Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections–A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial. Frontiers in pharmacology. 2021 Apr 30;12:981.

Yoo KJ, Keshavarzi F. Barriers and Enhancers of Medication Error Reporting Among Hospital Pharmacists, a Qualitative Exploration.

Zafar R, Raza ML. Assessment of look-alike, sound-alike and read-alike (Lasara) medicine–Errors in pharmacy. Journal of the College of Physicians and Surgeons--pakistan: JCPSP. 2020 Apr 1;30(4):425-8.

Keck T, Strobl A, Weinhaeusel A, Funk P, Michaelis M. Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections–A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial. Front. Pharmacol. 12: 666546. doi: 10.3389/fphar. 2021.666546. Frontiers in Pharmacology| www. frontiersin. org. 2021 Apr 30;12.

Mamat R, Awang SA. Development and psychometric validation of a questionnaire to evaluate knowledge and attitude towards medication error reporting among pharmacists. Drug, Healthcare and Patient Safety. 2020;12:95.

Seifert G, Funk P, Reineke T, Lehmacher W. Influence of EPs 7630 on Antipyretic Comedication and Recovery from Acute Tonsillopharyngitis in Children: A Meta-analysis of Randomized, Placebo-Controlled, Clinical Trials. Journal of Pediatric Infectious Diseases. 2021 May;16(03):122-8.

Seifert G, Funk P, Reineke T, Lehmacher W. Influence of EPs 7630 on Antipyretic Comedication and Recovery from Acute Tonsillopharyngitis in Children: A Meta-analysis of Randomized, Placebo-Controlled, Clinical Trials. Journal of Pediatric Infectious Diseases. 2021 May;16(03):122-8.

Riley DS, Lizogub VG, Heger M, Funk P, Mueller H, Lehmacher W. Treatment with EPs 7630, a Pelargonium sidoides root extract, is effective and safe in patients with the common cold: results from a randomized, double blind, placebo-controlled clinical trial. Integrative Medicine: A Clinician's Journal. 2019 Feb;18(1):42.

Ting LC, Moorthy K, Kee HW, Yee CW, Yee LW, Ni OA, Ting W. Service quality and outpatients satisfaction in public hospitals in Malaysia. International Journal of Public Policy and Administration Research. 2019;6(1):57-73.

Matthys H, Funk P. Pelargonium sidoides preparation EPs 7630 in COPD: health-related quality-of-life and other patient-reported outcomes in adults receiving add-on therapy. Current medical research and opinion. 2018 Jul 3;34(7):1245-51.

Seifert G, Brandes-Schramm J, Zimmermann A, Lehmacher W, Kamin W. Faster recovery and reduced paracetamol use–a meta-analysis of EPs 7630 in children with acute respiratory tract infections. BMC pediatrics. 2019 Dec;19(1):1-1.

Kamin W, Funk P, Seifert G, Zimmermann A, Lehmacher W. EPs 7630 is effective and safe in children under 6 years with acute respiratory tract infections: clinical studies revisited. Current medical research and opinion. 2018 Mar 4;34(3):475-85.

Schapowal A, Dobos G, Cramer H, Ong KC, Adler M, Zimmermann A, Brandes-Schramm J, Lehmacher W. Treatment of signs and symptoms of the common cold using EPs 7630-results of a meta-analysis. Heliyon. 2019 Nov 1;5(11):e02904.

Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. International journal of general medicine. 2018;11:91.

Hernández M, Tribiño G, Bustamante C. Caracterización de las potenciales interacciones farmacológicas en pacientes de una unidad de cuidados intensivos en un hospital de tercer nivel de Bogotá. Biomédica. 2018;38(3):407-16.

Hernández Londoño M. Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel (Bachelor's thesis, Universidad de La Sabana).

Hosseini E, Shojaei L, Karimpour H, Shahbazi F. Potential Drug-Drug Interactions in Critically Ill Medical Patients: A Cross-Sectional Study. Journal of Pharmaceutical Care. 2018:52-7.

Khan T, Muhammad K, Subhan F, Khan Z, Rehman NU. Frequency and nature of potential drug–drug interaction in medical wards: a cross-sectional study in a teaching hospital. Drugs & Therapy Perspectives. 2020 Apr;36(4):158-65.

Qassim S, Metwali Z, Al Hariri Y. WHY THERE IS A NEED FOR DRUG POST MARKETING SURVEILLANCE?.

BG P, Mishra O. Concept, Manufacturing and Characterization of Effervescent Tablets: A Review.